Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic

Trial Profile

Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Insomnia; Sleep disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jun 2017 Planned number of patients changed from 40 to 30.
    • 26 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 11 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top